sCD127 Biomarker for Sepsis Mortality Risk Evaluation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for evaluating mortality risk in patients with sepsis or septic shock, such as SOFA and SAPSII scores, are clinically impractical due to the need for active investigation and are not readily measurable, necessitating a more direct and rapid assessment tool.
Innovation Solution
A method involving the measurement of sCD127 expression in biological samples to predict mortality risk, utilizing soluble CD127 as a biomarker, which can be measured using automated analytical machines or rapid testing, providing a direct and measurable marker for evaluating mortality risk in patients with systemic inflammatory response syndrome or sepsis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional scoring systems (SOFA, SAPSII) are used to evaluate mortality risk, then comprehensive assessment of multiple physiological systems is achieved, but the method requires active investigation and is not readily measurable in clinical practice
Solution Approach 1:
The patent extracts the essential predictive information from complex multi-parameter scoring systems into a single soluble biomarker (sCD127). This biomarker captures the critical mortality risk assessment function while eliminating the need for comprehensive active investigation of multiple physiological parameters, making the assessment readily measurable and clinically practical.
Solution Approach 2:
The patent introduces sCD127 as an intermediary biomarker that mediates between the complex physiological state of septic patients and the clinical need for simple mortality risk assessment. This single measurable parameter serves as a bridge, translating complex pathophysiological processes into a straightforward clinical tool that maintains predictive accuracy while improving ease of operation.
2Reliability
If traditional scoring systems are used, then extensive clinical parameter investigation is required, but this increases the time and resources needed for assessment
Solution Approach 1:
The patent extracts the essential predictive information from time-consuming multi-parameter scoring systems into a single soluble biomarker (sCD127). This biomarker captures the critical mortality risk assessment function while eliminating the need for comprehensive active investigation of multiple physiological parameters, making the assessment readily measurable and clinically practical.
Solution Approach 2:
The patent employs sCD127 as a preliminary assessment tool that can be rapidly measured to provide immediate mortality risk evaluation. This single biomarker measurement serves as a preliminary screen that reliably stratifies patients before more comprehensive investigations are undertaken, reducing the overall time and resources required for complete patient assessment.
Data Source
AI summary
The invention provides a method of evaluating the risk of mortality in patients who present a systemic inflammatory response (SIRS) or septic syndromes, comprising measuring the expression of sCD127 in a biological sample.